Prometrika
Prometrika is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PKU (SYNPHENY-3)
Sponsor Synlogic Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome
Sponsor Stoke Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
Sponsor Point Biopharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Sponsor Mural Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Prometrika?
The 2026-10-09 snapshot links Prometrika to 11 distinct CTIS trials. Recorded services include Data management, Electronic data capture, Statistical analysis, Biostats, DSMC (data and safety monitoring committee), among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Prometrika?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Blood Disorders, Cardiology, Neurology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Prometrika conducted?
The linked trials record locations in 21 countries, including France, Spain, Italy, Germany, Netherlands. These are trial locations, not confirmed office locations or countries where Prometrika delivered services.
What can this page tell me about Prometrika's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Prometrika. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Prometrika
- Prometrika LLC